Clinical use of albumin

Blood Transfusion

Volumn 11, Issue SUPPL. 4, 2013, Pages

  Caraceni, Paolo ^a   Tufoni, Manuel ^a   Bonavita, Maria Elena ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Albumin; Ascites; Fluid resuscitation; Liver cirrhosis; Sepsis

Indexed keywords

ANTIBIOTIC AGENT; DIURETIC AGENT; HUMAN ALBUMIN; TERLIPRESSIN;

ASCITES; BACTERIAL PERITONITIS; CLINICAL TRIAL (TOPIC); CRITICAL ILLNESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; HEPATORENAL SYNDROME; HUMAN; INTENSIVE CARE UNIT; LIVER CIRRHOSIS; MICROANGIOPATHY; POST PARACENTESIS CIRCULATORY DYSFUNCTION; RESUSCITATION; REVIEW; SEPSIS; SEPTIC SHOCK;

HUMANS; SERUM ALBUMIN;

EID: 84885605625     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.005s     Document Type: Review

References (60)

1. Evans TW. Review article: albumin as a drug-biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002; 16 (Suppl 5): 6-11. (Pubitemid 41759557)
2. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth 2000; 85: 599-610.
3. Fanali G, di Masi A, Trezza V, et al. Human serum albumin: from bench to bedside. Mol Aspects Med 2012; 33: 209-90.
4. Garcia-Martinez R, Caraceni P, Bernardi M, et al. Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 2013; DOI 10.1002/hep.26338.
5. Sadler PJ, Tucker A, Viles JH. Involvement of a lysine residue in the N-terminal Ni2+ and Cu2+ binding site of serum albumins. Comparison with Co2+, Cd2+ and Al3+. Eur J Biochem 1994; 220: 193-200. (Pubitemid 24067569)
6. Sokołowska M, Wszelaka-Rylik M, Poznański J, Bal W. Spectroscopic and thermodynamic determination of three distinct binding sites for Co(II) ions in human serum albumin. J Inorg Biochem 2009; 103: 1005-13.
7. Kitano H, Fukui H, Okamoto Y, et al. Role of albumin and high-density lipoprotein as endotoxin-binding proteins in rats with acute and chronic alcohol loading. Alcohol Clin Exp Res 1996; 20: 73A-6A.
8. Chen TA, Tsao YC, Chen A, et al. Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol 2009; 44: 619-25.
9. Keaney JF, Simon DI, Stamler JS, et al. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest 1993; 91: 1582-9. (Pubitemid 23127360)
10. Kim SB, Chi HS, Park JS, et al. Effect of increasing serum albumin on plasma D-dimer, von Willebrand factor, and platelet aggregation in CAPD patients. Am J Kidney Dis 1999; 33: 312-7. (Pubitemid 29072234)
11. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.
12. Runyon BA; American Association for the Study of Liver Diseases (AASLD) Practice Guidelines. Management of adult patients with ascites due to cirrhosis: An update. Hepatology 2009; 49: 2087-107.
13. SAFE Study Investigators, Finfer S, McEvoy S, et al. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med 2011; 37: 86-96.
14. Delaney A, Dan A, McCaffrey J, Finfer S. The role of albumin as a resuscitation fluid for patients with sepsis: A systematic review and meta-analysis. Crit Care Med 2011; 39: 386-91.
15. Liumbruno GM, Bennardello F, Lattanzio A, et al. Recommendations for the use of albumin and immunoglobulins. Blood Transfus 2009; 7: 216-34.
16. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ 1998; 317: 235-40.
17. Wilkes MM, Navickis RJ. Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 135: 149-64. (Pubitemid 32738309)
18. Alderson P, Bunn F, Lefebvre C, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane database of systematic reviews 2004; 4: CD001208. DOI:10.1002/14651858.CD001208.pub2.
19. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350: 2247-56. (Pubitemid 38669207)
20. Alderson P, Bunn F, Li Wan Po A, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane database of systematic reviews 2011; 11: CD001208. DOI:10.1002/14651858.CD001208.pub3.
21. Myburgh J, Cooper DJ, Finfer S, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007; 357: 874-84. (Pubitemid 47347321)
22. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165-228.
23. Arroyo V, Fernandez J. Pathophysiological basis of albumin use in cirrhosis. Ann Hepatol 2011; 10 (Suppl 1): S6-14.
24. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-90.
25. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Postgrad Med J 2009; 85: 44-5425.
26. Salerno F, Gerbes A, Ginès P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgrad Med J 2008; 84: 662-70.
27. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-8. (Pubitemid 351615358)
28. Martín-Llahí M, Pépin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-9. (Pubitemid 351626950)
29. Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-8.
30. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-7. (Pubitemid 29247040)
31. Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47: 499-505. (Pubitemid 47331744)
32. Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. Cochrane database of systematic reviews 2012; 9: CD005162. DOI: 10.1002/14651858. CD005162.pub3.
33. Ruiz-del-Arbol L, Monescillo A, Jimenéz W, et al. Paracentesisinduced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 579-86. (Pubitemid 27351786)
34. Ginès P, Titó L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493-502.
35. Salerno F, Badalamenti S, Lorenzano E, et al. Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 1991; 13: 707-13.
36. Ginès A, Fernández-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002-10. (Pubitemid 26327603)
37. Sola-Vera J, Miñana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003; 37: 1147-53. (Pubitemid 36538692)
38. Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012; 55: 1172-81.
39. Rimola A, García-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000; 32: 142-53. (Pubitemid 30039459)
40. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 1495-501. (Pubitemid 24359062)
41. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-9. (Pubitemid 29362513)
42. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28: 26-42. (Pubitemid 351326531)
43. Sigal SH, Stanca CM, Fernandez J, et al. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007; 56: 597-9. (Pubitemid 46580522)
44. Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 2013; 11: 123-30.
45. Bernardi M, Maggioli C, Zaccherini G. Human albumin in the management of complications of liver cirrhosis. Crit Care 2012; 16: 211.
46. Clermont RJ, Vlahevic ZR, Chalmers TC, et al. Intravenous therapy of massive ascites in patients with cirrhosis. Longterm effects on survival and frequency of renal failure. Gastroenterology 1967; 53: 220-8.
47. Losowsky M, Atkinson M. Intravenous albumin in the treatment of diuretic-resistant ascites in portal cirrhosis. Lancet 1961; 2: 386-9.
48. Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999; 30: 639-45. (Pubitemid 29151905)
49. Romanelli RG, La Villa G, Barletta G, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. W J Gastroenterol 2006; 12: 1403-7.
50. Gentilini P, Bernardi M, Bolondi L, et al. The rational use of albumin in patients with cirrhosis and ascites. A Delphi study for the attainment of a consensus on prescribing standards. Dig Liv Dis 2004; 36: 539-46. (Pubitemid 41122196)
51. Guevara M, Terra C, Nazar A, et al. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol 2012; 57: 759-65.
52. Ginès P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 2008; 48: 1002-10.
53. Bañares R, Nevens F, Larsen FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. Hepatology 2012; 57: 1153-62.
54. Sen S, Williams R, Jalan R. Emerging indications for albumin dialysis. Am J Gastroenterol 2005; 100: 468-75. (Pubitemid 40314536)
55. Schaefer B, Schmitt CP. The role of molecular adsorbent recirculating system dialysis for extracorporeal liver support in children. Pediatr Nephrol 2013; 28: 1763-9.
56. Mirici-Cappa F, Caraceni P, Domenicali M, et al. How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. W J Gastroenterol 2011; 17: 3479-86.
57. Tanzi M, Gardner M, Megellas M, et al. Evaluation of the appropriate use of albumin in adult and pediatric patients. Am J Health Syst Pharm 2003; 60: 1330-5. (Pubitemid 46118103)
58. Tarín Remohí MJ, Sánchez Arcos A, Santos Ramos B, et al. Costs related to inappropriate use of albumin in Spain. Ann Pharmacother 2000; 34: 1198-205.
59. Debrix I, Combeau D, Stephan F, et al. Clinical practice guidelines for the use of albumin: results of a drug use evaluation in a Paris hospital. Tenon Hospital Paris. Pharm World 1999; 21: 11-6. (Pubitemid 29161693)
60. Vargas E, de Miguel V, Portolés A, et al. Use of albumin in two Spanish university hospitals. Eur J Clin Pharmacol 1997; 52: 465-70. (Pubitemid 27395646)